<!-- Latest compiled and minified CSS & JS -->
<link href="https://cdn.bootcss.com/bootstrap/3.3.7/css/bootstrap.min.css" rel="stylesheet">


<div class="container" style="margin-top: 20px">

    
    <div class="panel panel-info">

        <button type="button" class="close">
            <span aria-hidden="true">&times;</span>
        </button>

        <!-- Default panel contents -->
        <div class="panel-heading">
            <b>1. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.</b>
        </div>
        <div class="panel-body">

            <!-- Nav tabs -->
            <ul class="nav nav-tabs" role="tablist">
                <li role="presentation" class="active">
                    <a href="#abstract_30797499" aria-controls="abstract" role="tab" data-toggle="tab">Abstract</a>
                </li>
                <li role="presentation">
                    <a href="#abstract_cn_30797499" aria-controls="abstract_cn" role="tab" data-toggle="tab">Abstract_Chinese</a>
                </li>
            </ul>

            <!-- Tab panes -->
            <div class="tab-content well">
                <div role="tabpanel" class="tab-pane active" id="abstract_30797499">
                    <p>Non-small-cell lung cancer (NSCLC) has various driver mechanisms, including ROS1 rearrangement with different fusion patterns. There is a need to identify and evaluate new ROS1 fusions and the response to targeted therapy.</p>
                </div>
                <div role="tabpanel" class="tab-pane" id="abstract_cn_30797499">
                    <p>非小细胞肺癌（NSCLC）具有各种驱动机制，包括具有不同融合模式的ROS1重排。需要鉴定和评估新的ROS1融合和对靶向治疗的反应。</p>
                </div>
            </div>

            <a class="btn btn-sm btn-info" target="_blank" href="http://www.letpub.com.cn/index.php?page=journalapp&view=search&searchsort=relevance&searchname=Lung Cancer">
                Journal: Lung Cancer [IF=4.486]
            </a>

            <a class="btn btn-sm btn-warning" href="https://www.ncbi.nlm.nih.gov/pubmed/30797499" target="_blank">
                PMID: 30797499
            </a>

            <a class="btn btn-sm btn-success">
                PubDate: 2019-Mar
            </a>

            <a class="btn btn-sm btn-danger" title="Liu Y, Liu T, Li N, Wang T, Pu Y, Lin R">
                Authors: Liu Y, Liu T, Li ...
            </a>

            

            <form action="http://sci-hub.tw/" method="POST" style="display:inline" target="_blank">
                <input type="hidden" name="request" value="30797499">
                <input type="submit" value="PDF(Sci-Hub)" class="btn btn-sm btn-primary sci-hub">
            </form>

        </div>
    </div>
    
    <div class="panel panel-info">

        <button type="button" class="close">
            <span aria-hidden="true">&times;</span>
        </button>

        <!-- Default panel contents -->
        <div class="panel-heading">
            <b>2. A method to identify respiratory virus infections in clinical samples using next-generation sequencing.</b>
        </div>
        <div class="panel-body">

            <!-- Nav tabs -->
            <ul class="nav nav-tabs" role="tablist">
                <li role="presentation" class="active">
                    <a href="#abstract_30796243" aria-controls="abstract" role="tab" data-toggle="tab">Abstract</a>
                </li>
                <li role="presentation">
                    <a href="#abstract_cn_30796243" aria-controls="abstract_cn" role="tab" data-toggle="tab">Abstract_Chinese</a>
                </li>
            </ul>

            <!-- Tab panes -->
            <div class="tab-content well">
                <div role="tabpanel" class="tab-pane active" id="abstract_30796243">
                    <p>Respiratory virus infections are very common. Such infections impose an enormous economic burden and occasionally lead to death. Furthermore, every few decades, respiratory virus pandemics emerge, putting the entire world population at risk. Thus, there is an urgent need to quickly and precisely identify the infecting agent in a clinical setting. However, in many patients with influenza-like symptoms (ILS) the identity of the underlying pathogen remains unknown. In addition, it takes time and effort to individually identify the virus responsible for the ILS. Here, we present a new next-generation sequencing (NGS)-based method that enables rapid and robust identification of pathogens in a pool of clinical samples without the need for specific primers. The method is aimed at rapidly uncovering a potentially common pathogen affecting many samples with an unidentified source of disease.</p>
                </div>
                <div role="tabpanel" class="tab-pane" id="abstract_cn_30796243">
                    <p>呼吸道病毒感染很常见。这种感染造成巨大的经济负担，偶尔会导致死亡。此外，每隔几十年就会出现呼吸道病毒流行病，使全世界的人口处于危险之中。因此，迫切需要在临床环境中快速且精确地识别感染剂。然而，在许多患有流感样症状（ILS）的患者中，潜在病原体的身份仍然未知。此外，单独识别负责ILS的病毒需要时间和精力。在这里，我们提出了一种新的基于下一代测序（NGS）的方法，该方法能够快速，可靠地鉴定临床样品库中的病原体，而无需特异性引物。该方法旨在快速揭示影响具有未鉴定的疾病来源的许多样品的潜在常见病原体。</p>
                </div>
            </div>

            <a class="btn btn-sm btn-info" target="_blank" href="http://www.letpub.com.cn/index.php?page=journalapp&view=search&searchsort=relevance&searchname=Sci Rep">
                Journal: Sci Rep [IF=4.122]
            </a>

            <a class="btn btn-sm btn-warning" href="https://www.ncbi.nlm.nih.gov/pubmed/30796243" target="_blank">
                PMID: 30796243
            </a>

            <a class="btn btn-sm btn-success">
                PubDate: 2019-Feb-22
            </a>

            <a class="btn btn-sm btn-danger" title="Kustin T, Ling G, Sharabi S, Ram D, Friedman N, Zuckerman N, Bucris ED, Glatman-Freedman A, Stern A, Mandelboim M">
                Authors: Kustin T, Ling G,...
            </a>

            

            <form action="http://sci-hub.tw/" method="POST" style="display:inline" target="_blank">
                <input type="hidden" name="request" value="30796243">
                <input type="submit" value="PDF(Sci-Hub)" class="btn btn-sm btn-primary sci-hub">
            </form>

        </div>
    </div>
    
    <div class="panel panel-info">

        <button type="button" class="close">
            <span aria-hidden="true">&times;</span>
        </button>

        <!-- Default panel contents -->
        <div class="panel-heading">
            <b>3. Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?</b>
        </div>
        <div class="panel-body">

            <!-- Nav tabs -->
            <ul class="nav nav-tabs" role="tablist">
                <li role="presentation" class="active">
                    <a href="#abstract_30795628" aria-controls="abstract" role="tab" data-toggle="tab">Abstract</a>
                </li>
                <li role="presentation">
                    <a href="#abstract_cn_30795628" aria-controls="abstract_cn" role="tab" data-toggle="tab">Abstract_Chinese</a>
                </li>
            </ul>

            <!-- Tab panes -->
            <div class="tab-content well">
                <div role="tabpanel" class="tab-pane active" id="abstract_30795628">
                    <p>Acute myeloid leukemia (AML) is a clonal disease caused by genetic abberations occurring predominantly in the elderly. Next generation sequencing (NGS) analysis has led to a deeper genetic understanding of the pathogenesis and the role of recently discovered genetic precursor lesions (clonal hematopoiesis of indeterminate/oncogenic potential (CHIP/CHOP)) in the evolution of AML. These advances are reflected by the inclusion of certain mutations in the updated World Health Organization (WHO) 2016 classification and current treatment guidelines by the European Leukemia Net (ELN) and National Comprehensive Cancer Network (NCCN) and results of mutational testing are already influencing the choice and timing of (targeted) treatment. Genetic profiling and stratification of patients into molecularly defined subgroups are expected to gain ever more weight in daily clinical practice. Our aim is to provide a concise summary of current evidence regarding the relevance of NGS for the diagnosis, risk stratification, treatment planning and response assessment in AML, including minimal residual disease (MRD) guided approaches. We also summarize recently approved drugs targeting genetically defined patient populations with risk adapted- and individualized treatment strategies.</p>
                </div>
                <div role="tabpanel" class="tab-pane" id="abstract_cn_30795628">
                    <p>急性髓性白血病（AML）是由主要在老年人中发生的遗传性异常引起的克隆性疾病。下一代测序（NGS）分析已经导致对发病机制的更深入的遗传理解以及最近发现的遗传前体病变（不确定/致癌潜能的克隆性造血（CHIP / CHOP））在AML进化中的作用。这些进展反映在欧洲白血病网（ELN）和国家综合癌症网络（NCCN）更新的世界卫生组织（WHO）2016年分类和当前治疗指南中的某些突变，并且突变检测的结果已经影响了（目标）治疗的选择和时间安排。遗传分析和患者分层到分子定义的亚组预计将在日常临床实践中获得更多的权重。我们的目的是简要总结当前关于NGS在AML中的诊断，风险分层，治疗计划和反应评估的相关性的证据，包括最小残留病（MRD）指导方法。我们还总结了最近批准的针对遗传定义的患者群体的药物，其具有风险适应和个体化治疗策略。</p>
                </div>
            </div>

            <a class="btn btn-sm btn-info" target="_blank" href="http://www.letpub.com.cn/index.php?page=journalapp&view=search&searchsort=relevance&searchname=Cancers (Basel)">
                Journal: Cancers (Basel) [IF=5.326]
            </a>

            <a class="btn btn-sm btn-warning" href="https://www.ncbi.nlm.nih.gov/pubmed/30795628" target="_blank">
                PMID: 30795628
            </a>

            <a class="btn btn-sm btn-success">
                PubDate: 2019-Feb-21
            </a>

            <a class="btn btn-sm btn-danger" title="Leisch M, Jansko B, Zaborsky N, Greil R, Pleyer L">
                Authors: Leisch M, Jansko ...
            </a>

            

            <form action="http://sci-hub.tw/" method="POST" style="display:inline" target="_blank">
                <input type="hidden" name="request" value="30795628">
                <input type="submit" value="PDF(Sci-Hub)" class="btn btn-sm btn-primary sci-hub">
            </form>

        </div>
    </div>
    
    <div class="panel panel-info">

        <button type="button" class="close">
            <span aria-hidden="true">&times;</span>
        </button>

        <!-- Default panel contents -->
        <div class="panel-heading">
            <b>4. GANAB and PKD1 Variations in a 12 Years Old Female Patient With Early Onset of Autosomal Dominant Polycystic Kidney Disease.</b>
        </div>
        <div class="panel-body">

            <!-- Nav tabs -->
            <ul class="nav nav-tabs" role="tablist">
                <li role="presentation" class="active">
                    <a href="#abstract_30792735" aria-controls="abstract" role="tab" data-toggle="tab">Abstract</a>
                </li>
                <li role="presentation">
                    <a href="#abstract_cn_30792735" aria-controls="abstract_cn" role="tab" data-toggle="tab">Abstract_Chinese</a>
                </li>
            </ul>

            <!-- Tab panes -->
            <div class="tab-content well">
                <div role="tabpanel" class="tab-pane active" id="abstract_30792735">
                    <p>Autosomal Dominant Polycystic Kidney Disease (ADPKD) typically results from a mutation in the PKD1 and PKD2 genes, which code for polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Mutations in these genes promote renal cystic dysplasia and are a significant cause of End-Stage Kidney Disease (ESKD). Polycystic kidney disease-3 (PKD3), another form of ADPKD, is caused by mutations in glucosidase II alpha subunit (GANAB) gene and present in mid- and late adulthood. We report a description of an ADPKD case in a 12-year-old female presented bilateral renal cysts in adolescence. Two mutations in two genes PKD1 and GANAB were identified by targeted capture and next-generation sequencing (NGS) on an Illumina sequencing system. The identified PKD1 mutation p.Pro61Leu: c.182C &gt; T (CCC &gt; CTC) a missense type of uncertain clinical significance. However, the identified PKD1 mutation can alter transcription factors motifs and consequently disturb the transcription process. The second mutation identified in GANAB locus, p.Arg61Ter: c.181C &gt; T, a nonsense type, CGA &gt; TGA. The mutation is unreported pathogenic variant can cause loss of the glucosidase II alpha subunit normal protein function. Both the patient father and paternal grandmother had a history of ADPKD but never were tested. This case is the first case of combine presentation on PKD1 and PKD3 in a pediatric patient with nephrolithiasis.</p>
                </div>
                <div role="tabpanel" class="tab-pane" id="abstract_cn_30792735">
                    <p>常染色体显性遗传多囊肾病（ADPKD）通常由PKD1和PKD2基因的突变引起，其分别编码多囊蛋白-1（PC1）和多囊蛋白-2（PC2）。这些基因的突变促进肾囊性发育不良，并且是终末期肾病（ESKD）的重要原因。多囊肾病-3（PKD3），另一种形式的ADPKD，由葡糖苷酶IIα亚基（GANAB）基因突变引起，并存在于成年后期和晚期。我们报告了一名12岁女性在青春期出现双侧肾囊肿的ADPKD病例的描述。在Illumina测序系统上通过靶向捕获和下一代测序（NGS）鉴定两个基因PKD1和GANAB中的两个突变。鉴定的PKD1突变p.Pro61Leu：c.182C&gt; T（CCC&gt; CTC）具有不确定临床意义的错义类型。然而，鉴定的PKD1突变可以改变转录因子基序并因此干扰转录过程。第二个突变在GANAB基因座中鉴定，p.Arg61Ter：c.181C&gt; T，无义型，CGA&gt; TGA。该突变是未报告的致病变体，可导致葡糖苷酶IIα亚基正常蛋白功能丧失。患者父亲和祖母都有ADPKD病史但从未接受过检测。该病例是第一例在患有肾结石的儿科患者中联合呈现PKD1和PKD3的病例。</p>
                </div>
            </div>

            <a class="btn btn-sm btn-info" target="_blank" href="http://www.letpub.com.cn/index.php?page=journalapp&view=search&searchsort=relevance&searchname=Front Genet">
                Journal: Front Genet [IF=4.151]
            </a>

            <a class="btn btn-sm btn-warning" href="https://www.ncbi.nlm.nih.gov/pubmed/30792735" target="_blank">
                PMID: 30792735
            </a>

            <a class="btn btn-sm btn-success">
                PubDate: 2019
            </a>

            <a class="btn btn-sm btn-danger" title="Waldrop E, Al-Obaide MAI, Vasylyeva TL">
                Authors: Waldrop E, Al-Oba...
            </a>

            
            <a class="btn btn-sm btn-primary" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375066" target="_blank">
                PMC6375066
            </a>
            

            <form action="http://sci-hub.tw/" method="POST" style="display:inline" target="_blank">
                <input type="hidden" name="request" value="30792735">
                <input type="submit" value="PDF(Sci-Hub)" class="btn btn-sm btn-primary sci-hub">
            </form>

        </div>
    </div>
    
    <div class="panel panel-info">

        <button type="button" class="close">
            <span aria-hidden="true">&times;</span>
        </button>

        <!-- Default panel contents -->
        <div class="panel-heading">
            <b>5. Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient.</b>
        </div>
        <div class="panel-body">

            <!-- Nav tabs -->
            <ul class="nav nav-tabs" role="tablist">
                <li role="presentation" class="active">
                    <a href="#abstract_30788907" aria-controls="abstract" role="tab" data-toggle="tab">Abstract</a>
                </li>
                <li role="presentation">
                    <a href="#abstract_cn_30788907" aria-controls="abstract_cn" role="tab" data-toggle="tab">Abstract_Chinese</a>
                </li>
            </ul>

            <!-- Tab panes -->
            <div class="tab-content well">
                <div role="tabpanel" class="tab-pane active" id="abstract_30788907">
                    <p>Drive gene mutation positive non-small cell lung cancer achieves reliable clinical responses to subsequent target therapy. However, most patients will inevitably develop disease progression with multiple treatment failure. Next generation sequencing can identify clear resistance mechanisms. We report a case of a late stage, non-smoking, male non-small cell lung cancer patient that developed dual mutations and our attempts to determine the novel resistance mechanism. After systematic chemotherapy, he was administered multiple target therapy according to different genotypes. Larger panel gene detection was adapted after the failure of different treatments to investigate the resistance mechanism. Re-biopsy and large panel NGS revealed an EGFR mutant lung adenocarcinoma with alternating changes in acquired resistance between EGFR and ALK. The total survival time was 73 months. The genotypes and treatments in this patient provide new insight of target therapy resistance mechanisms. Re-biopsy and large panel gene detection should be performed for each driver gene mutation to provide precision treatment strategies.</p>
                </div>
                <div role="tabpanel" class="tab-pane" id="abstract_cn_30788907">
                    <p>驱动基因突变阳性非小细胞肺癌实现对随后靶向治疗的可靠临床反应。然而，大多数患者将不可避免地发展为多次治疗失败的疾病进展。下一代测序可以识别明确的抗性机制。我们报告了一例晚期，非吸烟，男性非小细胞肺癌患者发生双重突变和我们试图确定新的抗性机制。系统化疗后，根据不同的基因型进行多种靶向治疗。在不同处理失败后调整更大的小组基因检测以研究抗性机制。再活检和大面板NGS显示EGFR突变肺腺癌，EGFR和ALK之间的获得性抗性交替变化。总生存时间为73个月。该患者的基因型和治疗方法为目标治疗抵抗机制提供了新的见解。应对每个驱动基因突变进行再活检和大面板基因检测，以提供精确的治疗策略。</p>
                </div>
            </div>

            <a class="btn btn-sm btn-info" target="_blank" href="http://www.letpub.com.cn/index.php?page=journalapp&view=search&searchsort=relevance&searchname=Thorac Cancer">
                Journal: Thorac Cancer [IF=2.569]
            </a>

            <a class="btn btn-sm btn-warning" href="https://www.ncbi.nlm.nih.gov/pubmed/30788907" target="_blank">
                PMID: 30788907
            </a>

            <a class="btn btn-sm btn-success">
                PubDate: 2019-Feb-20
            </a>

            <a class="btn btn-sm btn-danger" title="Hu Y, Xiao L, Yang N, Zhang Y">
                Authors: Hu Y, Xiao L, Yan...
            </a>

            

            <form action="http://sci-hub.tw/" method="POST" style="display:inline" target="_blank">
                <input type="hidden" name="request" value="30788907">
                <input type="submit" value="PDF(Sci-Hub)" class="btn btn-sm btn-primary sci-hub">
            </form>

        </div>
    </div>
    

</div>



<script src="https://cdn.bootcss.com/jquery/3.3.1/jquery.min.js"></script>
<script src="https://cdn.bootcss.com/bootstrap/3.3.7/js/bootstrap.min.js"></script>


<script>
    $(document).ready(function () {
        $('.close').click(function () {
            $(this).parent().fadeOut();
        });

        $('.panel-heading').click(function () {
            $(this).next().fadeToggle();
            $(this).next().next().fadeToggle();
        });

        //var panels = ['panel-success', 'panel-info', 'panel-warning', 'panel-danger'];
        //$('.panel').each(function () {
        //    $(this).attr('class', )
        //});
    });
</script>